Breaking News

Juno Therapeutics and WuXi AppTec Form New Company

Focus will be on the development of cell-based cancer immunotherapies in China

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Juno Therapeutics and WuXi AppTec have started a new company in China—JW Biotechnology (Shanghai). The new company’s mission is to build China’s leading cell therapy company by leveraging Juno’s chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies together with WuXi AppTec’s R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solidorgan cancers. James Li, formerly a Kleiner Perkins partner and gene...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters